company background image
E2Z logo

Almirall DB:E2Z Stock Report

Last Price

€8.02

Market Cap

€1.7b

7D

3.0%

1Y

-5.3%

Updated

27 Mar, 2024

Data

Company Financials +

E2Z Stock Overview

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends2/6

Almirall, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Almirall
Historical stock prices
Current Share Price€8.02
52 Week High€9.79
52 Week Low€7.43
Beta0.32
1 Month Change-1.84%
3 Month Change-5.31%
1 Year Change-5.31%
3 Year Change-38.45%
5 Year Change-46.82%
Change since IPO-44.88%

Recent News & Updates

Recent updates

Shareholder Returns

E2ZDE PharmaceuticalsDE Market
7D3.0%4.0%2.5%
1Y-5.3%-24.6%7.0%

Return vs Industry: E2Z exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: E2Z underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is E2Z's price volatile compared to industry and market?
E2Z volatility
E2Z Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: E2Z has not had significant price volatility in the past 3 months.

Volatility Over Time: E2Z's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19431,904Carlos Gallardo Piquéhttps://www.almirall.com

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
E2Z fundamental statistics
Market cap€1.72b
Earnings (TTM)-€38.47m
Revenue (TTM)€898.79m

1.9x

P/S Ratio

-44.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E2Z income statement (TTM)
Revenue€898.79m
Cost of Revenue€235.30m
Gross Profit€663.49m
Other Expenses€701.96m
Earnings-€38.47m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 13, 2024

Earnings per share (EPS)-0.18
Gross Margin73.82%
Net Profit Margin-4.28%
Debt/Equity Ratio24.4%

How did E2Z perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

-97%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.